Population PKPD Mode.. - Pharsight Corporation

More documents

Recommendations

Info

Contact and Follow-Up: Thank you! James Hayden Senior Vice President, Global Sales Email: jhayden@pharsight.com Telephone: +1-650-314-3760 Internet Site (www.pharsight.com) slide 50 © Pharsight Corporation All Rights Reserved
Proprietary Notice ● All contents Copyright © 2008 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. ● No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, for any purpose, without the express written permission of Pharsight Corporation. ● WinNonlin, WNL, WinNonMix, WNM, Trial Simulator, TS2, Pharsight Knowledgebase Server, PKS, Drug Model Explorer, DMX and Pharsight are trademarks or registered trademarks of Pharsight Corporation. ● All other brand and product names are trademarks or registered trademarks of their respective holders. slide 51 © Pharsight Corporation All Rights Reserved
Page 1 and 2: Population PK/PD Modeling - The Pha
Page 3 and 4: Agenda Pharsight Company Overview R
Page 5 and 6: Who Is Pharsight? A company that he
Page 7 and 8: Who Are Pharsight Customers? This i
Page 9 and 10: Reporting and Analysis Services (RA
Page 11 and 12: RAS Value: High Quality Clinical Ph
Page 13 and 14: RAS Offers Three Analytic Competenc
Page 15 and 16: PK/PD Expertise in Early Drug Devel
Page 17 and 18: Communication Model: Single-Point C
Page 19 and 20: RAS Regulatory PK-PD Modeling RAS s
Page 21 and 22: Workflow: Population PK Analysis Pa
Page 23 and 24: QC/QA of the Analysis Dataset SAS D
Page 25 and 26: Regulatory and Timely POP PK/PD Pha
Page 27 and 28: PK Data PK from PHASE I, II and III
Page 29 and 30: Typical POP PK Model Development Wo
Page 31 and 32: Examples of GOF Plots Covariance ne
Page 33 and 34: Model Building : Adding Covariates
Page 35 and 36: Summary of Model building Absorptio
Page 37 and 38: Typical POP PK Model Development Wo
Page 39 and 40: Examples of Graphs to Aid Covariate
Page 41 and 42: Model Discrimination, Evaluation an
Page 43 and 44: What Can We Evaluate ? • The diff
Page 45 and 46: When to use diagnostics ? ● ●
Page 47 and 48: What to use in diagnostics ? ●
Page 49: Example of predictive check Drug RO

Population PKPD Mode.. - Pharsight Corporation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?